Skip to main content

Table 1 Study procedures and flow-chart

From: Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

  Screening 14 days d1, d30, d60, d90, d120 After the 4thmonth, every 3 months until tolerance or progession
Physical exam X X X
Safety X X X
Availbility of tumour sample X   
Thoracic and abdominopelvic CT-Scann X X X
Echocardio or MUGA X   X
Hematology INR TCA X X X
Biochemistry (1) X X X
Urine Dipstick X X X
Serum sample for TR programm   X  
  1. (1) Serum creatinine, Glomerular filtration rate (Cockroff and Gault), AST, ALT, Bilirubin, Alkaline phosphatases, Amylase and lipase, CPK.